Market moving insight and analysis.

Join Jim Kramer, David Faber, and me, Carl Kainteneah, on the opening bell hour of CNBC Squawk on the Street. Welcome to Squawk of the Street. I'm Carl Kintenea with Jim Kramer and post 9 of the New York Stock Exchange. Faber has the morning off. Futures have lost some gains as yields rise in response to this hot Q3 GDP print. 4-3, bested in a couple of years. Consumption solid,

the hottest headline on price at almost three years. Ten year is around 418. Our roadmap, though,

is going to begin with Novo Nordisk. Shares are up and pre-market on this FDA approval of the

company's weight loss pill. Plus the latest read on the American economy. Third quarter GDP, as we said, much stronger than expected.

Tesla's at small-time highs again, and the streets weighing in on the stock ahead of delivery numbers in a couple of weeks.

Let's begin, though, with Novo Nordisk up sharply in the pre-market, the FDA approving the company's Wagovi pill,

making it the first oral GLP1 cleared by regulators for weight loss.

Novo says it expects to launch the pill in the U.S. next month.

Some chatter today, Jim, about how much of a head start they have on Lilly?

You've got three months.

It is a surprise.

Now, remember that a pill is much preferred in a

country

versus the shot

uh... if you are taking wagovi

then people will move over quickly migrate to the wagovi pill because once you're

on one you don't see you don't because the doctors are afraid they're afraid

that look would let's say you are taking man jar right now now, Eli Lilly. They're reluctant to say, listen, you should go do what go be, because what they'll say is, listen, you tolerate Monjaro, and we just care about toleration. First, do no arm. Right. And that's been the way things go. And I think people who think, wow, there are people going to be really excited and move over

the pill. Their advice from the doctors is going to be, no, there could be different reactions.

And apparently the doses are so high that there are some different changes in diet that you

might have to do. We don't know enough about what the side effects are. We know this.

...